Concentra Sets CEO Salary At $785,000 And Preserves Former Chief’s Equity Awards
The leadership handoff includes a 125% target bonus for the CEO and salary protection that expands around a change in control.
Concentra Group Holdings Parent, which provides workplace healthcare, set president and CEO Matthew T. DiCanio’s salary at $785,000 a year, with a target bonus of 125% of salary, according to an SEC filing Monday. Former CEO William K. Newton’s move to executive chairman preserves continuity for his outstanding equity awards.
Pay For The Leadership Handoff
The previously announced transition took effect Sunday: DiCanio moved from president and CFO to president and CEO, William K. Newton became executive chairman, and Tanner Newton took over as executive vice president and CFO. Their employment agreements apply from that handoff.
William K. Newton will earn $550,000 annually, with a target bonus of 85% of salary. His initial contract runs through Concentra’s 2027 annual shareholder meeting, then renews for one-year terms unless terminated. The move out of the CEO job does not count as a departure for his equity awards or as grounds for a qualifying resignation.
Tanner Newton’s annual salary is $425,000, with a 75% target bonus. His contract begins with a one-year term and automatically renews for successive one-year periods unless terminated. DiCanio’s agreement continues until terminated, and the board will nominate him for election as a director while he remains CEO.
Concentra also awarded 164,894 restricted shares to DiCanio on Tuesday. William K. Newton received 138,812 shares; executives John A. deLorimier and Timothy Ryan received 46,543 each. The grants vest in equal installments on the first four grant anniversaries.
Salary Protection Around A Takeover
DiCanio is eligible for 24 months of continued salary if the company dismisses him without cause or he resigns for a contract-defined good reason, provided he signs a release of claims. That increases to 30 months if the qualifying departure falls within a window spanning three months before a change in control through 12 months afterward; all his unvested equity then vests immediately.
William K. Newton has 24 months of salary continuation for a qualifying departure, also subject to a release. His unvested equity likewise vests fully for a qualifying departure in that change-in-control window.
Tanner Newton’s corresponding salary protection is 18 months for dismissal without cause or resignation following a contract-defined termination event. Within the same change-in-control window, it rises to 24 months and his unvested equity vests fully.
All three agreements provide earned but unpaid prior-year bonuses, prorated termination-year bonuses with specified minimum-payment protections, company-paid continuation health coverage for up to 18 months, and proportional vesting of time-based equity awards outside the change-in-control provisions.
Workplace Clinics And Rising Sales
The handoff comes alongside third-quarter revenue of $622.1 million, up about 9% from a year earlier, in Concentra’s Thursday results announcement. Management raised its 2026 revenue forecast to $2.36 billion–$2.38 billion, from $2.325 billion–$2.375 billion.
Concentra treats work-related injuries and illnesses and offers physical exams, drug and alcohol screening, vaccinations and physical therapy. U.S. employers are its main customers, with payments primarily from employers, workers’ compensation insurers and third-party administrators.
At December 31, 2025, the company operated 628 stand-alone occupational health centers across 41 states and 411 employer-site clinics across 44 states. The stand-alone centers supplied approximately 93% of 2025 revenue; its other services include telemedicine, pharmacy and administration of substance-abuse testing.
Concentra will file the full employment agreements with its annual report for the fiscal year ending December 31, 2026.
Sources
- 8-K Filing — Concentra Group Holdings Parent, Inc. (CON) — SEC EDGAR
- Concentra Announces Results For Its Third Quarter Ended September 30, 2026 and Raises FY 2026 Guidance – Company Announcement - FT.com — Financial Times
- Concentra outlines raised 2026 outlook to $2.36B-$2.38B revenue and $505M-$510M adjusted EBITDA following leadership transition (NYSE:CON) | Seeking Alpha — seekingalpha.com
- Concentra (CON) Q3 2026 Earnings Call Transcript - The Globe and Mail — theglobeandmail.com